Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes. The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD).
Additionally, Novo Nordisk presented phase 2 data which demonstrate insulin degludec’s potential to achieve glycemic control when used once-daily or three times weekly in people with type 2 diabetes.
For the full press release click here.
